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Regulated secretion depends upon a highly coordinated
series of protein-protein and protein-lipid interactions. Two
phosphoinositides, phosphatidylinositol 4,5-bisphosphate
and phosphatidylinositol 3-phosphate, are important for the
ATP-dependent priming of the secretory apparatus prior to
Ca2-dependent exocytosis. Mechanisms that control phos-
phoinositide levels are likely to play an important role in prim-
ing fine tuning. Here we have investigated the involvement of
PIKfyve, a phosphoinositide 5-kinase that can phosphorylate
phosphatidylinositol 3-phosphate to produce phosphatidylino-
sitol 3,5-bisphosphate on large dense core vesicle exocytosis
fromneuroendocrine cells. PIKfyve localizes to a subpopulation
of secretory granules in chromaffin and PC12 cells. Nicotine
stimulation promoted recruitment of PIKfyve-EGFP onto
secretory vesicles in PC12 cells. YM-201636, a selective inhibi-
tor of PIKfyve activity, and PIKfyve knockdown by small inter-
fering RNA potentiated secretory granule exocytosis. Overex-
pression of PIKfyve or its yeast orthologue Fab1p inhibited
regulated secretion in PC12 cells, whereas a catalytically inac-
tive PIKfyve mutant had no effect. These results demonstrate a
novel inhibitory role for PIKfyve catalytic activity in regulated
secretion and provide further evidence for a fine tuning of exo-
cytosis by 3-phosphorylated phosphoinositides.
Neurotransmitters and hormones are released from their
storage vesicles into the extracellular space via calcium-
dependent exocytosis. Much work has been directed toward
identifying the proteins involved in and regulating the exocytic
process. These include members of the SNARE family of pro-
teins, synaptotagmins (1, 2, 4, 5, 13), and a host of regulatory
proteins, such as Munc18a (6, 7). In addition to the critical role
played by membrane proteins, there is an increasing amount of
literature pointing to the importance of lipids, in particular
phosphoinositides, in the regulation of membrane trafficking
events, including regulated exocytosis (8–13).
Phosphoinositides are generated by the reversible phospho-
rylation of the inositol head group of phosphatidylinositol
(PtdIns)2 by an array of kinases and phosphatases at one or
more of the 3-, 4-, and 5-OH positions (10). Previous studies
have highlighted the importance of a plasmamembrane pool of
phosphatidylinositol 4,5-bisphosphate for regulated exocytosis
of large dense core vesicles (LDCV) (14–17).
We recently demonstrated an involvement of the type II
PI3K,PI3K-C2, and itsproductPtdIns(3)P inpriming,anATP-
dependent step during which LDCV acquire the ability to fuse
with the plasma membrane (12). This novel role played by
PtdIns(3)P in promoting the priming stage of exocytosis has
opened a number of new research avenues regarding themech-
anism(s) regulating the concentration of PtdIns(3)P and the
potential role played by other 3-phosphorylated phosphoi-
nositides in neurosecretory cells.
Priming is a reversible step and must be tightly controlled to
prevent too many vesicles from reaching the primed state.
PtdIns(3)P levels could be negatively regulated in either or both
of twoways: throughdephosphorylation of PtdIns(3)P bymem-
bers of the myotubularin family of enzymes (18) or by further
phosphorylation of PtdIns(3)P on the 5-OH position to gener-
ate PtdIns(3,5)P2. The kinase responsible for this phosphoryla-
tion step in mammalian cells is PIKfyve (19, 20). PIKfyve is the
mammalian orthologue of the yeast Fab1p (20, 21). In yeast,
Fab1p is required for vacuolar membrane integrity and func-
tion (20, 21). Similarly, inmammalian cells, suppression of PIK-
fyve activity, either by overexpressing a kinase-inactive mutant
or by siRNA-mediated knockdown results in the accumulation
of enlarged internal membrane structures of endocytic origin
(22, 23). PIKfyvewas shown to be localized on early (24) and late
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endosomes (22). Evidence from an in vitro endosome fusion
assay suggested that PIKfyve may act as a negative regulator of
endosome fusion (22), whereas siRNA studies were consistent
with PIKfyve regulating endosome-TGN trafficking (23). Nota-
bly, PIKfyve has also been shown to regulate trafficking of
IRAP/GLUT4 vesicles to the plasma membrane in adipocytes
(25). This suggests that PIKfyve could play a pleiotropic role in
membrane trafficking, including on the exocytic pathway.
In this study, we have investigated the expression of PIKfyve
in neurosecretory cells and found that it partially localizes to
LDCV in an activity-dependent manner. We have used a com-
bination of pharmacological, overexpression, and siRNA
approaches to demonstrate that PIKfyve kinase activity plays a
critical role in controlling regulated exocytosis in neurosecre-
tory cells.
EXPERIMENTAL PROCEDURES
Antibodies—PIKfyve antiserum was raised by inoculating a
rabbit with a synthetic peptide corresponding to the last 18
amino acids of mouse PIKfyve (NP_035216). The specificity
and selectivity of this antibody for PIKfyve was confirmed by
Western blotting extracts of HEK293 cells transiently trans-
fected with pEGFP-C1 or PIKfyve-EGFP,Western blotting and
peptide competition and immunocytochemistry on PC12 cells
transiently transfected with pEGFP-C1 or PIKfyve-EGFP (Fig.
S1). This characterization demonstrated that the anti-PIKfyve
antibody is specific for and can detect human (HEK293 cells),
rat (PC12), and mouse (overexpressed) PIKfyve by both West-
ern blotting and immunocytochemistry. Other antibodies used
were anti-EEA1 (early endosomal antigen 1) (BD Transduction
Laboratories), anti-Syt1 (M48) (26), anti-P18 (27), and anti-
green fluorescent protein (Invitrogen).
Gel Electrophoresis and Immunoblotting—Tissue extracts
were prepared by homogenizing tissues at 4 °C in homogeniza-
tion buffer (20 mMHepes-NaOH, pH 7.4, 150 mMNaCl, 0.32 M
sucrose) containing 1mMdithiothreitol andComplete protease
inhibitor mixture (Roche Applied Science) with a Dounce
homogenizer. Cellular debris and nuclei were removed by low
speed centrifugation, and protein concentrations of the post-
nuclear supernatants were determined by Bradford reagent
(Bio-Rad) using a standard curve of purified IgG. Subcellular
fractionation of 3T3-L1 adipocytes (kind gift of R. Parton, Insti-
tute for Molecular Bioscience, Queensland, Australia) and
PC12 and chromaffin cells was carried out by scraping cells in
homogenization buffer as above. Samples were homogenized
by repeated passage through a 25-gauge needle, and cellular
debris and nuclei were removed by low speed centrifugation.
Membrane and cytosolic fractions were separated by centrifuga-
tion at 125,000 gav for 45min, and protein concentrations were
determinedasabove. 50gofprotein/fractionwas resuspended in
SDS sample buffer containing -mercaptoethanol, heated for 3
min at 95 °C, and analyzed by SDS-PAGE. Proteins were trans-
ferred onto polyvinylidene difluoride (0.2 m; Bio-Rad), blocked
in phosphate-buffered saline (PBS) containing 5% nonfat milk
(w/v), probed overnight at 4 °C with the indicated primary anti-
bodies, and detectedwith horseradish peroxidase-conjugated sec-
ondary antibody (1:5000; Pierce) for 1 h followed by enhanced
chemiluminescence (SuperSignal; Pierce).
Reverse Transcription-PCR—Total RNA was extracted from
rat subcutaneous adipose tissue, adrenal glands, and rat pheo-
chromocytoma (PC12) cells (ATCC) using the SV total RNA
isolation system (Promega). Poly(A) RNA was reverse tran-
scribed using oligo(dT)18 primers and used as a template for
PCR primers designed on the basis of the data base sequence of
rat PIKfyve XM_237217: forward (residues 910–931) and
reverse (residues 1209–1229). -Actin primers were chosen as
a positive control.
Catecholamine Secretion from Adrenal Chromaffin Cells—
Chromaffin cellswere prepared frombovine adrenal glands and
maintained in 24- or 96-well plates (Nunc) as previously
described (31). Intact cells were washed briefly oncewith buffer
A: 145 mM NaCl, 5 mM KCl, 1.2 mM Na2HPO4; 10 mM glucose;
20 mM HEPES-NaOH (pH 7.4), preincubated with the indi-
cated concentrations of inhibitors or inactive analogues for 20
min, and further stimulated for 20 min using high Kmodified
buffer A: KCl, increased to 60mM andNaCl decreased to 90mM
in the presence of 2mMCaCl2. Aliquots of the supernatantwere
taken at the end of each experiment, and cells were lysed with
1% (v/v) Triton X-100 (Sigma). Both sets of samples were
assayed fluorometrically for catecholamines, and the amount
released was expressed as a percentage of the total cate-
cholamine content of the cells (12, 28, 29). Plotted data are
representative of experiments carried out in quadruplicate and
performed at least four times.
PIKfyve siRNA—For siRNA targeting, rat PIKfyve cDNA
fragments TGACTTGCCTCACTCTCCT, encoding the
19-nucleotide siRNA sequence derived from the target tran-
script and separated from its reverse 19-nucleotide comple-
ment by a short spacer, were annealed and cloned in the BglII
and HindIII sites in front of the H1 promoter of a modified
pXGH5 plasmid encoding for growth hormone named pGH-
super as described previously (30). The human sequence
TGATTTGCCTCGATCTCCT was used as control (differ-
ences from rat sequence are underlined). Transfection effi-
ciency has been estimated by counting growth hormone-posi-
tive cells from 400–500 cells as described previously (30).
hGH Release from Transfected PC12 Cells—PC12 cells were
routinely cultured in Dulbecco’s modified Eagle’s medium sup-
plemented with 7.5% fetal bovine serum, 7.5% horse serum.
pXGH5 vector encoding hGH (1.2 g/well) either alone or
together with mammalian expression vectors encoding pro-
teins as indicated in Fig. 5 (1.2 g/well) were co-transfected in
PC12 cells with Lipofectamine 2000 (Invitrogen) in Opti-MEM
(Invitrogen) according to the manufacturer’s instructions.
Transfection efficiency was between 30 and 50%, and more
than 95% of transfected cells co-expressed hGHand the protein
of interest. 48 h after transfection, PC12 cells were briefly
washed in buffer A and either stimulated in high K buffer for
20min or pretreated for 20minwith either inhibitor or inactive
analogue prior to stimulation. Aliquots of the supernatant were
collected, and the cells detached using the remaining buffer
passing through a 25-gauge needle several times. The amount
of secretion from co-transfected cells was determined as per-
centage of total hGH/well using an hGH radioimmunoassay kit
(Nichols Institute) (12). Plotted data are representative of
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experiments carried out in triplicate andperformed at least four
times.
Immunocytochemistry and Live Cell Imaging—Cells seeded
on poly-L-lysine-coated coverslips were fixed with 4%
paraformaldehyde in PBS for 20 min, washed in PBS, and then
blocked for 1 h in PBS containing 3% normal horse serum, 0.5%
bovine serum albumin, 0.05% Triton X-100. For treatments,
cells were incubated for 20 min in Buffer A at 37 °C, 5% CO2
with the indicated concentrations of YM-201636 or
YM-211387 prior to fixation. A similar experiment was carried
out using nicotine stimulation prior to fixation in Buffer A con-
taining 2 mM Ca2. Coverslips were then incubated overnight
at 4 °C with primary antibodies and/or rhodamine-conjugated
phalloidin (Molecular Probes), washed with PBS, and revealed
using relevant secondary conjugated antibodies (Alexa488 and
Alexa546; 1:500;Molecular Probes) for 30min at room temper-
ature in the dark, followed by extensive washing and mounting
with Prolong Gold (Molecular Probes). In other experiments,
chromaffin cells (2–3 days of culturing) were permeabilized
with digitonin (Sigma) (20 M) in potassium glutamate buffer
(KGEP): 139 mM potassium glutamate, 5 mM glucose, 5 mM
EGTA, 20 mM PIPES-NaOH, 2 mM MgCl2, 2 mM ATP in the
continuing presence of boiled or unboiled ENTH-GST (6
g/ml) for 10min.Cellswerewashed inKGEPbuffer, fixed, and
processed for immunocytochemistry as described above and in
the figure legends. Samples were imaged with a laser-scanning
microscope (LSM 510; Zeiss). To illustrate the degree of colo-
calization, scatter diagramswere produced using LSM510 soft-
ware plotting the pixel intensity in the red and green channels
(x and y coordinates, respectively). Double-stained pixel (inten-
sity  100–150 arbitrary units) of the optical sections were
highlighted in white. Quantification of the degree of co-local-
ization was performed using the color range tool of LSM 510
software or Laserpix software (Bio-Rad). Briefly, immunoposi-
tive puncta were selected first in the green channel as regions of
interest. 30–110 regions of interest were selected per cell for at
least eight cells. Regions of interest with intensity  100–150
arbitrary units in both the green and red channels were consid-
ered co-localized. The percentage of co-localizing ROI was cal-
culated per image, and the mean and S.E. were calculated. This
process was repeated in the red channel. Quantification of the
area and size of the early endosomes was carried out by image
analysis on EEA1 staining using Laserpix software (Bio-Rad).
Briefly, clearly identifiable EEA1-positive structures were out-
lined, and area and size (length and width) measurement data
were acquired using the software.
Time Lapse Confocal Microscopy Imaging—Confocal micro-
scope (LSM 510 Meta; Zeiss) laser power was set at 4% for a
488-nm argon laser, and a 63 water immersion objective
(numerical aperture 0.93) was used. The pinhole was chosen
to give rise to confocal z sections less than 2.5 m. The fre-
quency of acquisition was 2 frames/min over the 10–15-min
incubation period. Cells were bathed in Buffer A containing 2
mMCa2, and nicotine (100M) was applied by injection using
a Hamilton syringe.
Analysis of Time Lapse Confocal Images—Labeled organelles
that remained in the same optical section throughout the dura-
tion of imaging were selected for intensity analysis. The
changes in intensity of PIKfyve staining in the cytosol and on
identified organelles were followed over time before and after
nicotine treatment. The values were expressed as percentage
increase of the normalized initial fluorescence intensity of
PIKfyve.
PIKfyve Inhibitor—YM-201636 was identified as an inhibitor
of PIKfyve by serendipity (31). It was shown to be a potent
PIKfyve inhibitor in a counterscreen directed at assessing the
specificity of inhibitors of p110. As for many other kinase
inhibitors, this compound appears to be ATP-competitive.
Constructs—PIKfyve cDNA in pBluescript vector (kindly
provided by A. Shisheva) was used as a template for site-di-
rectedmutagenesis (QuikChange; Stratagene).Mutant PIKfyve
contains a single amino acid substitution (K1831M) within the
kinase domain. This residue has been demonstrated to be crit-
ical for lipid kinase activity (32). Both wild-type and mutant
PIKfyve were inserted in pEGFP-C1 for mammalian expres-
sion. hGH-EGFP plasmid was kindly provided by I. Robinson
(33).
Statistical Analysis—Data analysis was carried out using Stu-
dent’s t test. Experiments were performed at least three times.
Values are expressed as mean S.E., and data were considered
significant at p  0.05 (*) and p  0.01 (**) unless otherwise
stated (Student’s t test).
RESULTS
To investigate PIKfyve expression and subcellular localiza-
tion in neurosecretory cells, a rabbit polyclonal antibody was
raised against a peptide corresponding to the last 18 amino
acids of mouse PIKfyve. This antibody was expected to cross-
react with both rat and human PIKfyve, since the predicted rat
PIKfyve orthologue, XM_237127 is identical within this 18-
amino acid stretch, and human PIKfyve (32) differs by only 1
amino acid. XM_237217 was identified as rat PIKfyve based on
data base searches and sequence alignments; the identity
between XM_237217 and mouse PIKfyve (NM_011086) is 93%
at the amino acid level, and within the kinase domain, the
amino acid identity is 99%, and all of the key residues previously
identified as being required for both lipid kinase and protein
kinase activity are present (32, 34).
PIKfyve was first identified in adipose tissue and skeletal
muscle (35) but has subsequently been reported to have a wider
tissue distribution (36). Our result from the antibody charac-
terization suggested that PC12 cells endogenously express PIK-
fyve (Fig. S1C). To confirm this, PIKfyve mRNA distribution
was investigated in rat adrenal glands, rat brain cortex, PC12
cells, and rat adipose tissue as a positive control (35). Using
PIKfyve-specific primers, a 310-bp fragment was detected in all
samples (Fig. 1A). -Actin primers were used as a positive con-
trol and to standardize the input. No bandwas detected in sam-
ples where the reverse transcriptase was omitted from the
reverse transcription reaction, demonstrating an absence of
contamination by genomicDNA (data not shown). The identity
of the 310-bp amplicon was confirmed as PIKfyve by DNA
sequencing (data not shown).
The distribution of PIKfyve expression in different rat tissues
was also investigated at the protein level by Western blotting
(Fig. 1B). Equal amounts of postnuclear supernatants of the
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tissues indicated were analyzed by SDS-PAGE and Western
blotting using anti-PIKfyve antibodies. Fig. 1B shows that PIK-
fyve is expressed in brain cortex, cerebellum, spinal cord, adre-
nal glands, liver, spleen, and testis. PIKfyve immunoreactivity
could not be detected in heart and kidney samples, which could
be due to a lack of expression in these tissues or to low expres-
sion below the levels of detection.
PIKfyve is distributed between cytosolic and membranous
compartments in 3T3-L1 adipocytes (34, 37). Membrane and
cytosolic fractions were prepared from 3T3-L1 adipocytes,
PC12 cells, and bovine adrenal chromaffin cells, and PIKfyve
distribution was determined by SDS-PAGE and Western blot-
ting using anti-PIKfyve antibodies (Fig. 1C). As previously
reported, we found more PIKfyve in 3T3-L1 adipocyte cytosol
than associated with cellular membranes (37). In both PC12
and adrenal chromaffin cells, PIKfyvewas present inmembrane
and cytosol fractions. We also ran an equal amount of purified
chromaffin granule membranes prepared as previously
described (12, 38, 39). Importantly, PIKfyve immunoreactivity
was also detected in the granule fraction, suggesting that PIK-
fyvemay be recruited to large dense core vesicles and could play
a role in secretory granule function.
To investigate a role for PIKfyve in exocytosis, we initially
focused on bovine adrenal chromaffin cells, a primary cell that
is a widely used model for studying neurosecretion. The local-
ization of PIKfyve on chromaffin granules observed byWestern
blotting (Fig. 1C) was confirmed by immunocytochemistry
using anti-PIKfyve and anti-P18 antibodies (Fig. 2A). P18 is a
proteolytic fragment of secretogranin II and amarker ofmature
secretory granules (27). PIKfyve immunoreactivity shows both
a diffuse and punctate localization, partially co-localizing with
P18 positive secretory granules (Fig. 2A).
The ability of PIKfyve to regulate LDCV exocytosis was
investigated using a novel, specific inhibitor of PIKfyve,
YM-201636 (31). This enabled us to investigate both the acute
and chronic effects of PIKfyve inhibition on exocytosis. Chro-
maffin cells were preincubated for 20min (Fig. 2, B–D) or over-
night (data not shown)with 800 nMYM-201636 or YM-211387,
an unrelated PI3K type I inhibitor, prior to stimulating secre-
tion by KCl-evoked depolarization. In acute treatments,
YM-201636 treatment significantly potentiated catecholamine
secretion by 35 3% (Fig. 2, B–D), whereas YM-211387 had no
effect (Fig. 2, C and D). A similar potentiation was observed
upon overnight incubation with YM-201636 (data not shown).
Increasing amounts of YM-201636 or YM-211387 were used to
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construct a concentration-response curve, which demon-
strated that 1 M YM-201636 caused maximal potentiation of
release (Fig. 2D). However, no potentiation was observed when
the concentration was raised to 10 M. This could be due to a
compound effect of the YM-201636. Since release experiments
on intact cells do not differentiate between an effect on the
releasemachinery or effects on volt-
age-gated calcium channels, chro-
maffin cells were preincubated with
800 nM YM-201636 or YM-211387
as before and permeabilized with
digitonin, and exocytosis was stim-
ulated using Ca2- and ATP-con-
taining buffer to bypass plasma
membrane calcium channels (Fig.
2E). A similar and significant
potentiation of exocytosis was
observed with YM-201636 but not
YM-211387, as was seen with
intact cells.
To investigate the effects of over-
expressing PIKfyve constructs on
secretion, we turned to the neu-
roendocrine PC12 cell line. The
effect of candidate protein overex-
pression on secretion can be assayed
by co-transfection with a plasmid
encoding hGH. The hGH is pack-
aged into secretory granules, and
exocytosed hGH can be detected
using a specific radioimmunoassay
(40, 41). First, co-localization studies were carried out by con-
focal microscopy to confirm that endogenous PIKfyve associ-
ates with secretory granules in this cell line as in chromaffin
cells (Fig. 3). PC12 cells were immunostainedwith anti-PIKfyve
antibodies together with antibodies against P18 (Fig. 3). PIK-
fyve immunostaining was found to be both diffuse throughout
the cytosol and punctate as expected from the subcellular frac-
tionation (Fig. 1C). A clear degree of co-localization was
detected between punctate PIKfyve and P18 (Fig. 3). However,
PIKfyve punctate staining did not completely co-localize with
P18, suggesting that PIKfyve is present on multiple organelles
in PC12 cells. Similarly, a fraction of P18 immunostaining did
not co-localize with PIKfyve, suggesting that PIKfyve is only
recruited on a subpopulation of mature secretory granules
under resting conditions. The immunostaining data, together
with the subcellular fractionation (Fig. 1C), demonstrate that
PIKfyve associates with a pool of mature LDCV.
Having established that PIKfyve immunoreactivity partially
co-localizes with P18 in chromaffin cells (Fig. 2A) and in PC12
cells (Fig. 3), we checked whether PIKfyve inhibition could also
affect exocytosis from PC12 cells. PC12 cells expressing hGH
were treated with 800 nM YM-201636 or YM-211387 and stim-
ulated by depolarization (Fig. 4A). YM-201636 significantly
potentiated depolarization-evoked hGH secretion by a similar
amount (42  9%) to that observed in chromaffin cells (35 
3%), whereas YM-211387 had no effect on secretion (Fig. 4A).
Neither YM-201636 nor YM-211387 (1M) affected the overall
distribution of LDCV by confocal microscopy (Figs. 4B and S2).
We next examined the effect of reducing endogenous levels
of PIKfyve on hGH release fromPC12 cells using RNA interfer-
ence. The level of knockdownwas found to be around 80% after
72 h of transfection with plasmids expressing PIKfyve-targeted
siRNAs versus control and mutated siRNAs (Fig. 5A). Impor-
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tantly, depolarization-induced hGH release was significantly
potentiated in PIKfyve siRNA cells versus controls (Fig. 5B).
Exocytosis from PC12 is therefore potentiated by both acute
inhibition of PIKfyve activity and by its knockdown, suggesting
that PIKfyve is a negative regulator of exocytosis.
To determine the effect of overexpressing PIKfyve and its
kinase-dead point mutant PIKfyve(K1831M) on hGH release,
PC12 cells were co-transfected with hGH and either PIKfyve-
EGFP or PIKfyve(K1831M)-EGFP. Overexpression of PIKfyve
wild type significantly inhibited depolarization-induced hGH
secretion (51 8%) in this system, whereas overexpressing the
kinase-dead PIKfyve point mutant had no significant effect on
hGH release (Fig. 5C). This suggests that PIKfyve catalytic
activity is required for the observed inhibition of exocytosis. To
further explore the negative role of PIKfyve catalytic activity,
PC12 cells were co-transfected with hGH and Fab1p, the yeast
orthologue of PIKfyve (20, 21). PIKfyve and Fab1p have previ-
ously been shown to functionally substitute for each other (20).
Importantly, overexpression of Fab1p-EGFP also inhibits depo-
larization-induced secretion to a similar extent as PIKfyve-
EGFP (35 9%) (Fig. 5C). Total hGH levelswere not affected by
overexpressing either the wild-type or catalytically inactive
kinases (data not shown).
PIKfyve has been implicated in regulation of endomem-
brane integrity, and in particular, the overexpression of the
PIKfyve(K1831E) mutant causes enlarged endosomal struc-
tures positive for PIKfyve andEEA1 (22) and at later time points
vacuolation (42). PC12 cells transfected with PIKfyve(K1831M)-
EGFP did contain enlarged PIKfyve(K1831M)-EGFP-positive
structures, the extent of which correlated with the levels of
overexpression (Fig. 6A and Table 1). These structures were
also positive for EEA1 (Fig. 6A), as described in other cell
types (22). The appearance of such enlarged EEA1-positive
structures can also be induced by short (20 min) incubations
with 10 M YM-201636 but not YM-211387 in untransfected
PC12 cells (Fig. S3) and, to a similar extent, in PC12 cells
overexpressing PIKfyve-EGFP (Fig. 6 and Table 1). Impor-
tantly, lower concentrations of YM-201636 that maximally
potentiate calcium-dependent catecholamine and hGH
release (Figs. 2D and 4A) did not result in the formation of
enlarged EEA1-positive structures (Fig. S3). This strongly
suggests that PIKfyve regulation of exocytosis and endoso-
mal size is independent. In contrast to other cell types, vac-
uolation visible by phase contrast was not observed in PC12
cells overexpressing PIKfyve(K1831M)-EGFP or PC12 cells
treated with high concentrations (10 M) of YM-201636
(data not shown).
Finally, we investigated the effect of stimulation of exocytosis
on PIKfyve-EGFP distribution by confocal time lapse micros-
copy. Consistent with the subcellular fractionation experiment
(Fig. 1C) and the immunocytochemistry study (Fig. 3), PIKfyve-
EGFP exhibited a cytosolic and punctate distribution when
expressed in PC12 cells. We performed time lapse confocal
microscopy analysis of PIKfyve-EGFPdistribution in PC12 cells
prior to and during nicotine stimulation (100 M). A rapid and
reversible recruitment of PIKfyve-EGFP from the cytosolic
pool to punctate structureswas observed (Fig. 7A), as evidenced
by an overall increase in fluorescence intensity on identified
organelles (Fig. 7, B andC) and a concomitant decrease in cyto-
solic fluorescence (Fig. 7C). Quantification of organelle fluores-
cence intensity revealed a 67  9% increase in fluorescence
intensity (example shown in Fig. 7B) occurring at the peak of
the effect, 365 36 s after nicotine addition to the bath (n 31
organelles) (Fig. 7D). To identify the nature of the organelles,
PIKfyve-EGFPwas recruited to uponnicotine stimulation, PIK-
fyve-EGFP-expressing PC12 cells were stimulated with nico-
tine (100 M) and fixed with paraformaldehyde, and the extent
of PIKfyve-EGFP co-localization with LDCV was assessed by
immunocytochemistry using anti-Syt1 antibodies (Fig. 7E).
The degree of co-localization was quantified in each case (Fig.
7F). Our result demonstrates that the degree of PIKfyve co-
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FIGURE 5. PIKfyve negatively regulates exocytosis of hGH from PC12
cells. A, PC12 cells were transfected with either the pGHsuper vector (No
siRNA), the pGHsuper-PIKfyve siRNA vector (PIKfyve siRNA), or the pGHsuper-
PIKfyve mutated siRNA vector (mutated siRNA). 72 h after transfection, pro-
teins were extracted, and 20-g samples were analyzed by Western blot
using anti-PIKfyve and anti-actin antibodies. A, semiquantitative analysis of
the PIKfyve levels detected in PC12 cells transfectedwith the various vectors.
Quantification was performed using scanning densitometry analysis of the
Western blots and is presented as mean values S.E. of three independent
experiments. Data have been normalized for transfection efficiency (60–
65%). B, 72 h after transfection, the cells were incubated for 10 min in the
absence (Resting;openbars) or presenceof 59mMK (Stimulated; closed bars).
hGH release is expressed as the percentage of total hGH present in the cells
before the 10-min stimulation period. C, PIKfyve-EGFP expression inhibits
hGH exocytosis from PC12 cells. PC12 cells transiently transfected with hGH
and either control plasmid (EGFP-C1), PIKfyve-EGFP, PIKfyve(K1831M)-EGFP,
or Fab1p-EGFP were incubated for 20 min in the absence or presence of 59
mM K buffer A to stimulate exocytosis. hGH release is expressed as the per-
centage of total hGH present in the cells before the 10-min stimulation
period. Data are given as the mean values  S.E. obtained in three experi-
ments performed on three different cell cultures (n 3). *, p 0.05; **, p
0.005 (Student’s t test, one-tailed; n 3).
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localization with a LDCV marker, Syt1, is significantly
increased upon stimulation of exocytosis by nicotine treatment,
20.0  5.2% in unstimulated cells (n  9 cells) versus 45.5 
8.5% in stimulated cells (n  10 cells), suggesting that upon
stimulation of exocytosis, PIKfyve is indeed recruited from the
cytosol to a subpopulation of LDCV. Since PIKfyve plays a role
in exocytosis, it is likely that its recruitment takes place on
mature secretory granules. PIKfyve-EGFP was found to par-
tially co-localize with P18 immunostaining, a marker of
mature secretory granules. Importantly, the level of co-local-
ization was significantly enhanced in nicotine-stimulated
PC12 cells (Fig. S4).
Our results demonstrate that PIKfyve is located on secretory
granules. Since PIKfyve uses PtdIns(3)P as substrate to generate
PtdIns(3,5)P2, we investigated the presence of PtdIns(3,5)P2 on
secretory granules using the ENTHdomain from yeast Ent3p, a
specific PtdIns(3,5)P2 effector (43). In permeabilized chromaf-
fin cells, ENTH staining was punctate. A good degree of co-
localization was found with Syt1, strongly suggesting that
PtdIns(3,5)P2 could indeed be present on a subpopulation of
secretory granules (Fig. 8).
Together, the data using inhibitors and overexpression indi-
cates that PIKfyve kinase activity is involved in negatively reg-
ulating calcium-dependent exocytosis of secretory granules in
neuroendocrine cells.
DISCUSSION
In this study, we have used overexpression studies, RNA
interference, and a novel inhibitor to demonstrate a role for the
phosphoinositide kinase, PIKfyve, in LDCV exocytosis from
neurosecretory cells.
We have first demonstrated that PIKfyvemRNA and protein
are present in neuroendocrine tissues, including rat brain and
adrenal glands. In PC12 and chromaffin cells, PIKfyve is both
cytosolic and associated with punctate structures. From our
co-localization studies, it appears that there are multiple vesic-
ular pools of PIKfyve in neurosecretory cells, including a pool
co-localizing with P18 and Syt1 on LDCV. In PC12 cells, PIK-
fyve is dynamically regulated. Upon nicotine stimulation, there
is a transient recruitment of PIKfyve from the cytosol to punc-
tate structures, including LDCV. A previous study demon-
strated an insulin-dependent relocation of PIKfyve from a cyto-
solic to low density membrane fraction biochemically (37).
Thus, recruitment of PIKfyve to cellular membranes in
response to extracellular stimuli may be an important regulator
of membrane trafficking events.
The combination of pharmacological inhibitor, RNA inter-
ference knockdown, and overexpression evidence points to
PIKfyve playing a negative role in regulated secretion. Indeed,
overexpression of PIKfyve and its yeast orthologue, Fab1p,
inhibits hGH secretion in PC12 cells, whereas acute treatment
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FIGURE 6. Expression of PIKfyve(K1831M)-EGFP andhigh concentrations
of YM201636 promote an enlargement of early endosomal structures in
PC12 cells. A, PC12 cells were transiently transfected with PIKfyve-EGFP and
PIKfyve(K1831M)-EGFP and where indicated were treated with 10 M
YM-201636 or YM-211387 for 20 min prior to fixation. Cells were immunola-
beled using anti-EEA1 antibodies. Images are 0.5-m confocal z-sections;
scale bar, 10 m. B, size of early endosomes in the indicated conditions was
quantified by image analysis as described under “Experimental Procedures”
and expressed as a percentage of control untransfected cells. For absolute
values of area and size, see Table 1.WT, wild type.
TABLE 1
Measurement of various parameters of PC12 cells early endosomes (EE) labeled with EEA1
Results of the image analysis shown are representative of the average S.E. of the indicated parameters.
PC12 cells Early endosomal parametersArea Length Width
m2 m m
Untransfected (6 cells, 263 EE) 0.169 0.007 0.462 0.017 0.325 0.011
Transfected PIKfyve(K1831M) (3 cells, 71 EE) 0.434 0.061 0.789 0.069 0.622 0.048
Transfected PIKfyve-WT (3 cells, 83 EE) 0.115 0.002 0.370 0.004 0.244 0.004
Untransfected YM-201636 (10 M) (5 cells, 153 EE) 0.513 0.0194 0.871 0.017 0.596 0.014
Untransfected YM-211387 (10 M) (5 cells, 186 EE) 0.155 0.005 0.444 0.010 0.312 0.004
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with PIKfyve inhibitor and PIKfyve knockdown using siRNA
both potentiated LDCV exocytosis. However, interfering with
PIKfyve activity by overexpression of the kinase-inactive
mutant of PIKfyve showed no effect on secretion. This could be
related to the defects in endosomal morphology that occur
upon overexpression of themutant PIKfyve. In agreement with
this, low concentrations of YM-201636 that potentiate exocy-
tosis do not cause endosomal enlargement, whereas higher
concentrations that do cause endosomal enlarging do not
potentiate exocytosis.
Evidence from GLUT4 translocation would support this
idea, since overexpression of a PIKfyve mutant unable to be
phosphorylated by protein kinase B was shown to promote
GLUT-4 vesicle exocytosis (25), whereas the PIKfyve(K1831E)
kinase-inactivemutantwas inhibitory forGLUT4 translocation
(34, 44). This discrepancy was thought to arise as a side effect of
the gross morphological defects caused by the PIKfyve kinase-
inactivemutant (25). Altogether, our data point to an inhibitory
role for PIKfyve catalytic activity in calcium-dependent LDCV
exocytosis.
There are a number of possible explanations for the negative
impact of PIKfyve on secretion. One possibility is that PIKfyve
could help decrease the levels of PtdIns(3)P known to promote
LDCVpriming (12). In order to avoid toomany LDCV reaching
the primed state at a given time, ATP-dependent primingmust
be tightly controlled. Phosphorylation of PtdIns(3)P by PIKfyve
to PtdIns(3,5)P2 would decrease PtdIns(3)P levels and as a
result negatively regulate priming. PtdIns(3,5)P2 production
itself might have a negative impact on secretion, potentially
acting as a competitive antagonist for the phosphatidylinositol
4,5-bisphosphate effector Syt1. A recent study highlighted a
role for Akt/protein kinase B in catecholamine release from
chromaffin cells (45) and suggested that PIKfyve could play a
role in this pathway (25). Further work is required to address
these important points.
The negative effect of PIKfyve on exocytosis could also ema-
nate from a trafficking effect. It has been proposed that the
enlarged EEA1-positive structures visible in PIKfyve kinase-in-
active-expressing cells at early time points are a result of an
increased fusion of early endosomes, the role of endogenous
PIKfyve therefore being inhibitory for early endosome fusion
(22). However, RNA interference knockdown of PIKfyve, while
resulting in a similar increase in size of EEA1-positive endo-
somes, led to the conclusion that PIKfyve positively regulates
endosome-TGN trafficking where a decrease in this trafficking
step leads to an accumulation of membrane in endosomes (23).
A similar conclusion was reached in a study investigating the
role of protein kinase B phosphorylation of PIKfyve in 3T3-L1
adipocytes (25). A PIKfyve mutant that cannot be phosphoryl-
FIGURE 7. Activity-dependent recruitment of PIKfyve-EGFP on LDCV.
A, PC12 cells transiently transfectedwith PIKfyve-EGFPwere visualized by con-
focal time lapsemicroscopyprior to andduringnicotine (100M) stimulation.
B, example of the time course of PIKfyve-EGFP recruitment on one identified
organelle (the acquisition time is indicated below each image in min). The
fluorescence intensity was assigned according to the indicated pixel fluores-
cence intensity scale. C, the time course of the PIKfyve-EGFP fluorescence
intensity on identified organelles (F-organelle) and in the cytosol (F-cytosol)
were measured and analyzed (n  6 regions of interest located either on
organelles or in the cytosol;meanS.E.).D, peak fluorescence intensity at the
maximum of nicotine effect was calculated as a percentage of control. *, p
0.05 (Student’s t test, one-tailed). E, PC12 cells transiently transfected with
PIKfyve-EGFP were stimulated with nicotine (100 M), fixed, and processed
for Syt1 immunoreactivity. F, the percentage of PIKfyve-positive organelles
co-localizing with Syt1-positive LDCVs was quantified as described under
“Experimental Procedures.” n  9–10 cells examined/condition, 422–464
organelles analyzed/condition. Scale bar, 5 m.
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ated by protein kinase B enhances insulin-stimulated IRAP
translocation to the plasma membrane. Since PIKfyve in these
cells is found on a population of endosomal vesicles that move
away from the cell periphery, it is proposed that PIKfyve promotes
an endosomal to TGN trafficking step, and by blocking this, the
mutant increases the amount of insulin-responsive aminopepti-
dase in an insulin-sensitive recycling endosome pool (25).
In neuroendocrine cells, it is therefore possible that PIKfyve
could be involved in the maturation of secretory granules from
immature to mature secretory granules. This process requires
the homotypic fusion of immature secretory granules and the
budding of membrane from the immature secretory granule
that traffics back to the TGN (46). However, future studies are
required to investigate these alternatives.
It is becoming increasingly clear that phosphoinositides can
function in a number of different processes within the cell,
depending on the site of local synthesis. For example, there is
evidence that phosphatidylinositol 4,5-bisphosphate plays a
role in coordinating both exocytosis and endocytosis at the syn-
apse (10, 11, 13, 47), whereas
PtdIns(3)P, a lipid best character-
ized for its role in early endosome
function (48), has also been shown
to be involved in lysophosphatidic
acid-stimulated cell migration (49),
ATP-dependent priming in neuro-
secretory cells (12), and transloca-
tion of GLUT4-containing vesicles
to the plasma membrane (50, 51).
An important pointwas therefore to
investigate whether PtdIns(3,5)P2 is
produced upon stimulation of exo-
cytosis. We attempted to detect
changes in global PtdIns(3,5)P2 lev-
els upon stimulation of exocytosis in
32P-labeled cells by HPLC analysis.
However, due to the relatively low
levels of PtdIns(3,5)P2, this analy-
sis was unsuccessful. Possible rea-
sons for this include the presence
of phosphatases causing the turn-
over of PtdIns(3,5)P2 or that
PtdIns(3,5)P2 may only be gener-
ated at a very restricted location
with very little change in whole
cell PtdIns(3,5)P2 levels. Using
the PtdIns(3,5)P2-selective probe
ENTH (from the yeast Ent3p), we
show a selective binding to LDCV,
suggesting that PtdIns(3,5)P2 might
indeed localize on a discrete sub-
population of chromaffin granules.
Further study should address the
dynamic role played by this pool of
PtdIns(3,5)P2 in LDCV exocytosis.
Our results indicate that PIKfyve
may function at multiple trafficking
steps in neurosecretory cells. As
seen in nonneuronal cells, our results support an important role
of PIKfyve in endosomal dynamics. However, PIKfyve also clearly
localizes to a subpopulation of LDCV, a dynamic process that
seems to be increased by stimulation of exocytosis. The combina-
tion of inhibitor and overexpression studies here demonstrates
that PIKfyve also functions in the regulated exocytic pathway.
Finally, many of the proteins and lipids involved in calcium-de-
pendent exocytosis in neurosecretory cells also play a role in neu-
rotransmitter release from small synaptic vesicles. The possibility
that PtdIns(3)P, PtdIns(3,5)P2, and their respective kinases may
also be important for synaptic vesicle and/or dense core vesicle
exocytosis in neurons remains to be addressed.
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g/ml) in KGEP buffer, washed, and fixed and processed for Syt1 immunostaining (A and B). A control
experiment was carried out with the same concentration of preboiled ENTH (A). Confocal images of boiled (A)
and unboiled (B) ENTH (green) and Syt1 (red) immunostaining of a single chromaffin cell. Partial co-localization
(yellow) in themerge image canbe observed (B). Co-localized pixels (100 arbitrary units in both red and green
channels) were highlighted (in white) in the optical sections highlighting the punctate nature of the co-local-
ized area (B, bottom). Images are confocal z-sections taken every 1 m; scale bar, 5 m. Note that we consis-
tently observed a nuclear ENTH staining.
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Supplemental Fig. 1: anti-PIKfyve antibody characterisation. (A) Proteins from HEK293 cells 
transiently transfected with EGFP-C1, PIKfyve-EGFP or control (no DNA) were separated by SDS-
PAGE and Western blotted in parallel with anti-PIKfyve or anti-GFP. The anti-PIKfyve antibody 
recognises a band of ~220 kDa. (B) Pre-incubation of anti-PIKfyve with a molar excess of raising 
peptide abolishes immunoreactivity. (C) PC12 cells were transfected with PIKfyve-EGFP or EGFP 
alone, fixed and immunostained with the anti-PIKfyve antibody. Anti-PIKfyve immunoreactivity 
(red) was seen in all cells but to a much higher extent in PIKfyve-EGFP-positive cells (green).  
 
Supplemental Fig. 2: PC12 cells transiently transfected with hGH-EGFP were imaged by confocal 
microscopy before and following application of 800 nM YM-201636 at the indicated time points. 
YM-201636 was added at t = 0.5 minutes. Images are 0.5 μm confocal z-sections. 
 
Supplemental Fig. 3: PC12 cells were treated with indicated concentrations of YM-201636 or YM-
211387 for 20 minutes prior to fixation and immunocytochemistry using anti-EEA1 antibodies. 
Images are 0.5 μm confocal z-sections; scale bar 10 μm. 
 
 
Supplemental Fig. 4: PC12 cells transiently transfected with PIKfyve-EGFP were stimulated with 
nicotine (100 μM) for 5 min, fixed and processed for P18 immunostaining. Confocal microscopy 
image of control and stimulated cells were quantified for co-localisation. Images are 0.5 μm 
confocal z-sections; scale bar 10 μm. 
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